Imprimis’ staff members will work with physicians, insurance companies and pharmacy benefit managers to facilitate the insurance payment process for patients enrolled in the ICAN program.
Imprimis is largely focusing on expanding access to a treatment for patients with cystinuria, a chronic genetic condition that leads to the formation of kidney stones. The company’s tiopronin delayed release medication prevents kidney stone formation in adults who did not respond to dietary changes or increased fluids.
Tiopronin serves as an alternative to the drug Thiola developed by San Diego-based Retrophin. Tiopronin’s National Drug Code will allow patients and insurance companies to receive more than a 70 percent reduction in costs compared to Thiola, according to Imprimis.
The drugmaker says its compounded form of tiopronin will not only lower treatment costs, but also reduce the number of pills patients must take every day to manage the condition.
More articles on supply chain:
Treatment for rare degenerative neuromuscular disease earns orphan drug status
What is the cost of discarding unused surgical supplies?
Study prompts formal recommendations for insulin injections
